WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Healing the Mind and Heart: Post-COVID Effects on Brain and Heart—A Clinical Outlook

Dr. Shivaashish K A V S

Vidya Nursing Home

ABSTRACT

The COVID-19 pandemic, caused by SARS-CoV-2, has had widespread ramifications not only during the acute infection phase but also in its aftermath. According to WHO estimates, approximately 3.7% of individuals infected globally (about 144.7 million by end of 2021) developed post-COVID condition, with nearly 15% reporting persistent symptoms at 12 months. While initial estimates placed the global prevalence at approximately 3.7% by late 2021, ongoing surveillance indicates that the long-term burden of post-COVID conditions persists, with continued research into evolving prevalence rates as new SARS-CoV-2 variants emerge and vaccination rates increase. Increasing evidence highlights the significant and persistent effects on both the neurological and cardiovascular systems, often referred to as "long COVID" or post-acute sequelae of SARS-CoV-2 infection (PASC). This article reviews the most recent literature and clinical findings related to the neurological and cardiological consequences of COVID-19. Emphasis is placed on manifestations such as cognitive dysfunction, depression, autonomic disturbances, myocarditis, and postural orthostatic tachycardia syndrome (POTS), with discussion on pathophysiology, clinical findings, diagnostic strategies, and management.

Keywords: Long COVID, PASC, Neurological complications, Cardiac sequelae, SARS-CoV-2, Post-COVID Syndrome

1. Introduction

Since its emergence in 2019, COVID-19 has infected hundreds of millions worldwide. While most recover fully, a substantial subset experiences prolonged symptoms affecting multiple organ systems. WHO reports that about 3.7% of all infected individuals developed long COVID, and 15% of them still experience symptoms after one year. These post-COVID conditions (PCCs) often persist for weeks to months and significantly affect quality of life. Neurological and cardiovascular symptoms are among the most frequently reported. Recent multicenter studies have demonstrated the long-term impact of COVID-19 on brain function and cardiac health, emphasizing the need for a focused review to better guide clinicians in post-pandemic care.

2. Neurological Sequelae of COVID-19

2.1. Epidemiology and Clinical Presentation

Studies suggest that up to 30-50% of patients recovering from COVID-19 report at least one neurological symptom. WHO statistics indicate 79.5 neurological sequelae per 1,000 persons within three years post-infection. Common manifestations include:

- Cognitive impairment ("brain fog")
- Headache
- Dizziness
- Sleep disturbances
- Depression and anxiety
- Peripheral neuropathy
- Anosmia and ageusia

Beyond common neurological symptoms, a significant subset of patients experiences post-exertional malaise (PEM), a characteristic feature often seen in conditions like Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), highlighting a potential overlap in underlying mechanisms.

2.2. Mechanisms of Neurological Injury

The pathophysiology includes:

- Direct viral invasion via ACE2 receptors on neurons and glial cells
- Immune-mediated injury (cytokine storm)
- Hypoxia-induced injury
- Microvascular thrombi and endotheliitis

Neuroinflammation is central, leading to white matter abnormalities and hippocampal atrophy noted on neuroimaging in some studies (e.g., Lancet 2022, UK Biobank study). Furthermore, emerging research is exploring the role of metabolic dysregulation within the brain and the potential for persistent viral reservoirs contributing to these long-term neurological symptoms.

2.3. Neuropsychiatric Complications

Depression and anxiety are highly prevalent. WHO reported a 25% global increase in anxiety and depression during the first year of the pandemic. A meta-analysis (Taquet et al., Lancet Psychiatry, 2021) revealed that one-third of COVID-19 survivors develop neuropsychiatric conditions within 6 months.

2.4. Diagnostic Approach

- MRI brain for cognitive deficits or persistent headaches
- EEG for altered mental status or seizures
- Neuropsychological testing
- Biomarkers: IL-6, CRP, D-dimer

Ongoing research is exploring more specific biomarkers, such as neurofilament light chain (NfL), which may indicate neuronal injury and aid in diagnosis and prognosis in the future.

2.5. Management

- Multidisciplinary rehabilitation
- Cognitive behavioral therapy (CBT)
- SSRI/SNRI for mood symptoms
- Sleep hygiene and physical exercise

3. Cardiological Sequelae of COVID-19

3.1. Clinical Manifestations

Cardiovascular symptoms are prevalent even in patients with mild acute illness. WHO reports approximately 33 cardiovascular sequelae per 1,000 survivors, with 16.9 disability-adjusted life years (DALYs) lost per 1,000 over three years. Symptoms include:

- Palpitations
- Chest pain
- Dyspnea on exertion
- Fatigue
- Syncope

3.2. Myocardial Injury and Myocarditis

Myocarditis has been frequently reported post-infection and post-vaccination. CMR (cardiac MRI) shows myocardial edema and late gadolinium enhancement in up to 60% of patients (Puntmann et al., JAMA Cardiol, 2020).

3.3. Postural Orthostatic Tachycardia Syndrome (POTS)

A notable subset of patients—especially young females—develop POTS post-COVID, characterized by:

- HR increase >30 bpm on standing
- Orthostatic intolerance
- Dizziness and fatigue

This is thought to result from autonomic nervous system dysfunction. WHO describes clusters of POTS-like symptoms under long COVID.

3.4. Arrhythmias and Thromboembolism

- Atrial fibrillation
- QT prolongation
- Increased incidence of DVT, PE, and microthrombosis

3.5. Diagnostic Tools

- ECG, Holter monitoring
- Troponins, BNP
- Echocardiography
- Cardiac MRI
- Tilt-table test for POTS

3.6. Management Strategies

- Beta-blockers or Ivabradine for tachycardia
- Anticoagulation when indicated
- Lifestyle changes: increased fluid/salt intake, compression stockings
- Physical reconditioning

Management strategies for POTS often include a combination of increased fluid and salt intake, compression stockings, and a carefully tailored physical reconditioning program, with emphasis on individual tolerance to avoid post-exertional symptom exacerbation. Pharmacological interventions such as beta-blockers or Ivabradine may also be employed to manage tachycardia.

4. Special Populations

4.1. Elderly

Higher risk of long COVID, particularly neurocognitive decline. Delirium is often an early sign in elderly COVID patients. WHO estimates nearly 1 in 4 elderly COVID-19 survivors experience persistent neurological or cardiac symptoms.

4.2. Pediatric and Adolescent Patients

Post-COVID multisystem inflammatory syndrome (MIS-C) can involve cardiac dysfunction and neurological symptoms.

5. Future Directions and Conclusion

Post-COVID conditions are now recognized as a distinct clinical entity with neurological and cardiac manifestations being prominent. WHO stresses the need for integrated, multidisciplinary long COVID clinics. The long-term burden necessitates collaboration among neurology, cardiology, rehabilitation, and mental health professionals. Ongoing trials are evaluating a range of interventions, including various anti-inflammatory agents, immunomodulators, autonomic stabilizers, and neuroprotective strategies, with some early research also exploring the potential role of antivirals for individuals with suspected persistent viral reservoirs. As we transition from pandemic response to long-term care, it is imperative to recognize and validate patient symptoms while developing standardized diagnostic and therapeutic pathways.

References

- Taquet M, et al. Lancet Psychiatry. 2021;8(5):416-427.
- Puntmann VO, et al. JAMA Cardiology. 2020;5(11):1265-1273.
- UK Biobank Neuroimaging Study. Lancet. 2022.
- CDC Post-COVID Conditions:

https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html

- WHO Post COVID-19 Condition:

https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition

- WHO Global COVID-19 Dashboard and Burden Estimates.

https://www.who.int/data

- Nature Medicine. Long-term outcomes of COVID-19.

https://www.nature.com/articles/s41591-022-01934-0